Jason Ryan
About Jason Ryan
Jason Ryan Board Member
Jason Ryan serves as a Board Member, leveraging his extensive experience in the biotechnology and healthcare sectors. His career spans various high-ranking roles, demonstrating a solid background in financial and operational leadership. With a track record in leading firms through critical developments and growth phases, Ryan brings a wealth of expertise to board discussions and strategic decisions.
Jason Ryan Experience as COO and CFO of Magenta Therapeutics
Jason Ryan served as the Chief Operating Officer (COO) and Chief Financial Officer (CFO) of Magenta Therapeutics. His tenure focused on developing therapeutics for autoimmune diseases and blood cancers. Magenta Therapeutics, known for its innovative approaches in the life sciences sector, benefited from Ryan's combined operational and financial oversight, enhancing the company’s capabilities in meeting its strategic goals.
Jason Ryan CFO at Foundation Medicine
Jason Ryan previously held the role of CFO at Foundation Medicine. During his time there, he successfully navigated the company through its initial public offering (IPO) and spearheaded its global commercialization efforts. His financial leadership was instrumental in positioning Foundation Medicine as a significant player in the precision medicine sector.
Jason Ryan Board of Directors at ArcherDX, Inc.
Jason Ryan served on the board of directors of ArcherDX, Inc. His experience in the biotechnology and healthcare industries contributed to the board's strategic initiatives. During his tenure, ArcherDX, Inc. worked on expanding its molecular diagnostic solutions, benefiting from Ryan's insights and governance.
Jason Ryan Education and Early Career
Jason Ryan holds a Bachelor of Arts in Economics from Bates College and a Master of Business Administration from Babson College. He began his career at Deloitte & Touche, where he earned his Certified Public Accountant (CPA) designation. This early experience in a leading accounting and consulting firm laid the foundation for his subsequent roles in financial leadership within the healthcare and biotechnology sectors.